MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 329015 | Name: Dexlansoprazole
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Dexlansoprazole, also known as Dexilant and TAK-390MR, is a proton pump inhibitor that employs a novel release formulation that prolongs its absorption. Dexlansoprazole is used to treat non-erosive gastroesophageal reflux disease.

Chemical Structure

Dexlansoprazole
Dexlansoprazole
CAS#138530-94-6 (free base)

Theoretical Analysis

MedKoo Cat#: 329015

Name: Dexlansoprazole

CAS#: 138530-94-6 (free base)

Chemical Formula: C16H14F3N3O2S

Exact Mass: 369.0759

Molecular Weight: 369.36

Elemental Analysis: C, 52.03; H, 3.82; F, 15.43; N, 11.38; O, 8.66; S, 8.68

Price and Availability

Size Price Availability Quantity
250mg USD 250.00 2 Weeks
500mg USD 350.00 2 Weeks
1g USD 550.00 2 Weeks
2g USD 750.00 2 Weeks
5g USD 950.00 2 Weeks
10g USD 1,650.00 2 Weeks
20g USD 2,950.00 2 Weeks
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
313640-86-7 (sesquihydrate) 138530-94-6 (free base)
Synonym
Dexlansoprazole; Dexilant; Kapidex; TAK-390; TAK 390; TAK390; (+)-Lansoprazole; R-(+)-Lansoprazole; T-168390; T168390; T 168390;
IUPAC/Chemical Name
(R)-2-(((3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole
InChi Key
MJIHNNLFOKEZEW-RUZDIDTESA-N
InChi Code
InChI=1S/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22)/t25-/m1/s1
SMILES Code
O=[S@@](C1=NC2=CC=CC=C2N1)CC3=NC=CC(OCC(F)(F)F)=C3C
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 369.36 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. Dexlansoprazole. 2022 May 15. PMID: 30000653. 2: Aslam N, Wright R. Dexlansoprazole MR. Expert Opin Pharmacother. 2009 Oct;10(14):2329-36. doi: 10.1517/14656560903198978. PMID: 19708852. 3: Abel C, Desilets AR, Willett K. Dexlansoprazole in the treatment of esophagitis and gastroesophageal reflux disease. Ann Pharmacother. 2010 May;44(5):871-7. doi: 10.1345/aph.1M685. Epub 2010 Apr 6. PMID: 20371754. 4: Hershcovici T, Jha LK, Fass R. Dexlansoprazole MR: a review. Ann Med. 2011 Aug;43(5):366-74. doi: 10.3109/07853890.2011.554429. Epub 2011 Mar 3. PMID: 21366513. 5: Emerson CR, Marzella N. Dexlansoprazole: A proton pump inhibitor with a dual delayed-release system. Clin Ther. 2010 Aug;32(9):1578-96. doi: 10.1016/j.clinthera.2010.08.008. PMID: 20974316. 6: Croxtall JD, Scott LJ. Dexlansoprazole modified release: in erosive oesophagitis and non-erosive reflux disease. Drugs. 2010 Aug 20;70(12):1593-601. doi: 10.2165/11295960-000000000-00000. PMID: 20687622. 7: Frelinger AL 3rd, Lee RD, Mulford DJ, Wu J, Nudurupati S, Nigam A, Brooks JK, Bhatt DL, Michelson AD. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers. J Am Coll Cardiol. 2012 Apr 3;59(14):1304-11. doi: 10.1016/j.jacc.2011.12.024. Erratum in: J Am Coll Cardiol. 2012 Aug 7;60(6):566-7. PMID: 22464259. 8: Chiang HH, Wu DC, Hsu PI, Kuo CH, Tai WC, Yang SC, Wu KL, Yao CC, Tsai CE, Liang CM, Wang YK, Wang JW, Huang CF, Chuah SK; Taiwan Acid-Related Disease Study Group. Clinical efficacy of 60-mg dexlansoprazole and 40-mg esomeprazole after 24 weeks for the on-demand treatment of gastroesophageal reflux disease grades A and B: a prospective randomized trial. Drug Des Devel Ther. 2019 Apr 26;13:1347-1356. doi: 10.2147/DDDT.S193559. PMID: 31118571; PMCID: PMC6499145. 9: Fass R, Frazier R. The role of dexlansoprazole modified-release in the management of gastroesophageal reflux disease. Therap Adv Gastroenterol. 2017 Feb;10(2):243-251. doi: 10.1177/1756283X16681701. Epub 2017 Jan 5. PMID: 28203282; PMCID: PMC5298478. 10: Skrzydło-Radomańska B, Radwan P. Dexlansoprazole - a new-generation proton pump inhibitor. Prz Gastroenterol. 2015;10(4):191-6. doi: 10.5114/pg.2015.56109. Epub 2015 Dec 16. PMID: 26759624; PMCID: PMC4697039. 11: Behm BW, Peura DA. Dexlansoprazole MR for the management of gastroesophageal reflux disease. Expert Rev Gastroenterol Hepatol. 2011 Aug;5(4):439-45. doi: 10.1586/egh.11.37. PMID: 21780890. 12: Addendum: Dexlansoprazole for GERD. Med Lett Drugs Ther. 2022 May 16;64(1650):79-80. PMID: 35536912. 13: Jiao Q, Zou F, Li S, Wang J, Xiao Y, Guan Z, Dong L, Tian J, Li S, Wang R, Zhang J, Li H. Dexlansoprazole prevents pulmonary artery hypertension by inhibiting pulmonary artery smooth muscle cell to fibroblast transition. Am J Transl Res. 2022 Aug 15;14(8):5466-5479. PMID: 36105026; PMCID: PMC9452313. 14: Grady H, Murakawa Y, Mulford D, Kukulka M. Development of Dexlansoprazole Delayed-Release Capsules, a Dual Delayed-Release Proton Pump Inhibitor. J Pharm Sci. 2019 Nov;108(11):3496-3501. doi: 10.1016/j.xphs.2019.07.023. Epub 2019 Aug 3. PMID: 31386865. 15: Wedemeyer RS, Blume H. Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update. Drug Saf. 2014 Apr;37(4):201-11. doi: 10.1007/s40264-014-0144-0. PMID: 24550106; PMCID: PMC3975086. 16: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. Proton Pump Inhibitors. 2019 Apr 15. PMID: 31643228. 17: Fock KM, Ang TL. Dexlansoprazole, a modified release formulation of an enantiomer of lansoprazole, for the treatment of reflux esophagitis. Curr Opin Investig Drugs. 2008 Oct;9(10):1108-15. PMID: 18821474. 18: Frye JW, Peura DA. Managing gastroesophageal reflux disease - comparative efficacy and outcomes of dexlansoprazole MR. Ther Clin Risk Manag. 2015 Oct 30;11:1649-56. doi: 10.2147/TCRM.S66680. PMID: 26586949; PMCID: PMC4634831. 19: Metz DC, Vakily M, Dixit T, Mulford D. Review article: dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release proton pump inhibitor therapy. Aliment Pharmacol Ther. 2009 May 1;29(9):928-37. doi: 10.1111/j.1365-2036.2009.03984.x. Epub 2009 Feb 26. PMID: 19298580. 20: Lespessailles E, Toumi H. Proton Pump Inhibitors and Bone Health: An Update Narrative Review. Int J Mol Sci. 2022 Sep 14;23(18):10733. doi: 10.3390/ijms231810733. PMID: 36142643; PMCID: PMC9504265.